Updating results

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Type 2 diabetes: empagliflozin (ESNM35)

This evidence summary has been replaced by NICE technology appraisal guidance 336.

Evidence summary Published March 2014

Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

This evidence summary has been updated and replaced by NICE guideline NG10.

Evidence summary Published March 2014

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

Advice on the use of the Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns to aid local decision-making

Medtech innovation briefing Published February 2014

The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

Advice on the use of the PressureWire fractional flow reserve measurement system for coronary artery disease to aid local decision-making

Medtech innovation briefing Published February 2014

The NGAL Test for early diagnosis of acute kidney injury (MIB3)

Advice on the use of the NGAL Test for early diagnosis of acute kidney injury (AKI) to aid local decision-making

Medtech innovation briefing Published February 2014

Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)

This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]

Evidence summary Published February 2014

The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

Advice on the use of the RhinoChill intranasal cooling system for reducing temperature after cardiac arrest to aid local decision-making

Medtech innovation briefing Published February 2014

Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

Summary of the evidence on subcutaneous depot medroxyprogesterone acetate (DMPA-SC) for long-acting reversible contraception..

Evidence summary Published January 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)

April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.

Evidence summary Published December 2013

Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)

Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making

Evidence summary Published December 2013

Alcohol dependence: nalmefene (ESNM29)

This evidence summary has been replaced by NICE technology appraisal guidance 325.

Evidence summary Published December 2013

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)

This evidence summary has been replaced by NICE technology appraisal guidance 335

Evidence summary Published October 2013

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 2 diabetes: lixisenatide (ESNM26)

Summary of the evidence on lixisenatide (glucagon-like peptide-1 [GLP-1] mimetic) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 1 diabetes: insulin degludec (ESNM24)

Summary of the evidence on insulin degludec for treating type 1 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

Evidence summary Published July 2013

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published June 2013

Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published June 2013

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

Summary of the evidence on fluticasone furoate plus vilanterol for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published June 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

Summary of the evidence on lisdexamfetamine dimesylate for attention defecit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published May 2013

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

Evidence summary Published April 2013

Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

Summary of the evidence on linaclotide for irritable bowel syndrome (IBS) with constipation in adults to inform local NHS planning and decision-making

Evidence summary Published April 2013

Schizophrenia: lurasidone (ESNM15)

This evidence summary has been replaced by ESNM48

Evidence summary Published April 2013

Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

Summary of the evidences on clonidine for attention deficit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published April 2013

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013